R1 Therapeutics

Executive Summary

R1 Therapeutics is a private, renal-focused biotechnology company based in San Diego, California, founded in 2020. The company aims to develop innovative small molecule therapeutics for kidney diseases, addressing significant unmet medical needs in nephrology. While specific pipeline details are not publicly disclosed, R1 Therapeutics leverages its expertise in renal biology and small molecule drug discovery to target diseases such as chronic kidney disease (CKD), diabetic nephropathy, and other renal disorders. Given the high prevalence of kidney disease and the limited therapeutic options available, R1 Therapeutics has the potential to become a key player in the nephrology space. The company's strategy likely involves advancing preclinical candidates toward clinical trials, seeking partnerships with larger pharmaceutical companies, and securing additional funding to support its research and development efforts. As an early-stage company, R1 Therapeutics faces typical risks including clinical failure, regulatory hurdles, and competition from other renal-focused biotechs.

Upcoming Catalysts (preview)

• H2 2026Preclinical Data Readout for Lead Program60% success
• H1 2026Series A Funding Announcement70% success
• 2026Collaboration or Licensing Agreement with Pharma Partner40% success